Acorda Therapeutics Inc. (ACOR)

3.39
0.18 5.04
NASDAQ : Health Technology
Prev Close 3.57
Open 3.58
Day Low/High 3.26 / 3.68
52 Wk Low/High 2.27 / 27.85
Volume 2.27M
Avg Volume 1.49M
Exchange NASDAQ
Shares Outstanding 48.08M
Market Cap 185.10M
EPS 0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Acorda Therapeutics To Host Conference Call To Discuss Third Quarter Results On October 22, 2015

Acorda Therapeutics To Host Conference Call To Discuss Third Quarter Results On October 22, 2015

Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that it will host a conference call and webcast to report its third quarter 2015 financial results and pipeline updates on Thursday, October 22 at 8:30 a.

Insider Trading Alert - ACOR, TIPT And NUAN Traded By Insiders

Insider Trading Alert - ACOR, TIPT And NUAN Traded By Insiders

Stocks with insider trader activity include ACOR, TIPT and NUAN

Acorda to Present New rHIgM22 and AMPYRA® (dalfampridine) Data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Acorda to Present New rHIgM22 and AMPYRA® (dalfampridine) Data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will present new analyses of pharmacokinetic data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS), and...

Acorda Therapeutics (ACOR) Is Today's Perilous Reversal Stock

Acorda Therapeutics (ACOR) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a "perilous reversal" (up big yesterday but down big today) candidate

Acorda Recognized With Legal Media Group 2015 Life Sciences Award

Acorda Recognized With Legal Media Group 2015 Life Sciences Award

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that its legal team has been recognized with a Legal Media Group 2015 Life Sciences Award as a "Hatch-Waxman Impact Case of the Year.

Acorda Therapeutics (ACOR) Is Today's Strong On High Volume Stock

Acorda Therapeutics (ACOR) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a strong on high relative volume candidate

Acorda Named One Of The 100 Best Workplaces For Women By Fortune And Great Place To Work

Acorda Named One Of The 100 Best Workplaces For Women By Fortune And Great Place To Work

Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named as one of the 100 Best Workplaces for Women based on an independent survey by Fortune and Great Place to Work ®.

RSI Alert: Acorda Therapeutics (ACOR) Now Oversold

RSI Alert: Acorda Therapeutics (ACOR) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Acorda Therapeutics To Present At The Baird 2015 Healthcare Conference

Acorda Therapeutics To Present At The Baird 2015 Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Michael Rogers, Chief Financial Officer, will present at the Baird 2015 Healthcare Conference in New York on Wednesday, September 9 at 2:00pm.

Interesting ACOR Put And Call Options For April 2016

Interesting ACOR Put And Call Options For April 2016

Investors in Acorda Therapeutics Inc saw new options become available this week, for the April 2016 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 231 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Acorda Therapeutics (ACOR) Stock Climbs After Panel Dismisses Patent Challenge

Acorda Therapeutics (ACOR) Stock Climbs After Panel Dismisses Patent Challenge

Acorda Therapeutics (ACOR) shares are rising after a panel dismissed a patent challenge of components in the company's multiple sclerosis treatment.

Pre-Market Activity Shows Heavy Volume And Movement For Acorda Therapeutics (ACOR)

Pre-Market Activity Shows Heavy Volume And Movement For Acorda Therapeutics (ACOR)

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a pre-market mover with heavy volume candidate

Acorda Announces Patent Trials And Appeal Board (PTAB) Denies Both IPRs Of AMPYRA Patents

Acorda Announces Patent Trials And Appeal Board (PTAB) Denies Both IPRs Of AMPYRA Patents

Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) will not institute the inter partes review (IPR) of U.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CARV, HSKA, JNP, LOGM, SPRO Downgrades: A, ACOR, CAM, DBD, NL, PNRG, RDHL, REXR, SHLM, SUNS, TCAP, TRGP, TUMI Initiations: AST, PGN Read on to get TheStreet Quant Ratings' detailed report:

Acorda Therapeutics To Present At The Canaccord Genuity Growth Conference

Acorda Therapeutics To Present At The Canaccord Genuity Growth Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Michael Rogers, Chief Financial Officer, will present at the Canaccord Genuity Growth Conference in Boston on Wednesday, August 12 at 4:00pm.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACOR, CORR, TIS Downgrades: ATAI, BG, CATM, CMPR, CPA, HTWR, KRNY, MTGE, SFUN, SPN, TMHC Initiations: IMPR Read on to get TheStreet Quant Ratings' detailed report:

Acorda Provides Financial And Pipeline Update For 2015 Second Quarter

Acorda Provides Financial And Pipeline Update For 2015 Second Quarter

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a financial and pipeline update for the second quarter ended June 30, 2015.

Acorda Awarded Grant To Study ARCUS® Technology In Respiratory Distress Syndrome

Acorda Awarded Grant To Study ARCUS® Technology In Respiratory Distress Syndrome

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the Bill & Melinda Gates Foundation has awarded the Company a $1.

Acorda Therapeutics Stock Sees Short Interest Decline 10.7%

Acorda Therapeutics Stock Sees Short Interest Decline 10.7%

The most recent short interest data has been released by the NASDAQ for the 06/30/2015 settlement date, which shows a 817,508 share decrease in total short interest for Acorda Therapeutics Inc , to 6,821,401, a decrease of 10.70% since 06/15/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Acorda Data On Inhaled Levodopa Therapy CVT-301 Recognized In Blue Ribbon Highlights Session At International Congress Of Parkinson's Disease And Movement Disorders

Acorda Data On Inhaled Levodopa Therapy CVT-301 Recognized In Blue Ribbon Highlights Session At International Congress Of Parkinson's Disease And Movement Disorders

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that data from a Phase 2b clinical trial of CVT-301, an inhaled levodopa (L-dopa) under development for the episodic treatment of OFF episodes associated with...

First Week of August 21st Options Trading For Acorda Therapeutics (ACOR)

First Week of August 21st Options Trading For Acorda Therapeutics (ACOR)

Investors in Acorda Therapeutics Inc saw new options become available this week, for the August 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new August 21st contracts and identified one put and one call contract of particular interest.

Chart Trends in Airgas, Acorda Therapeutics

Chart Trends in Airgas, Acorda Therapeutics

Weekly support allows time for daily recoveries.

Acorda Presents Data On Inhaled Levodopa Therapy CVT-301 At International Congress Of Parkinson's Disease And Movement Disorders

Acorda Presents Data On Inhaled Levodopa Therapy CVT-301 At International Congress Of Parkinson's Disease And Movement Disorders

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today presented data from a Phase 2b clinical trial of CVT-301, an inhaled levodopa (L-dopa) under development for the episodic treatment of OFF episodes associated with Parkinson's...

Acorda CEO Ron Cohen Named BIO Chairman For 2015-2016 Term

Acorda CEO Ron Cohen Named BIO Chairman For 2015-2016 Term

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that President and Chief Executive Officer Ron Cohen, M.

Acorda Therapeutics To Present At The Jefferies Global Healthcare Conference

Acorda Therapeutics To Present At The Jefferies Global Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, President and Chief Executive Officer and Michael Rogers, Chief Financial Officer, will present at the Jefferies Global Healthcare Conference in New...

Insider Trading Alert - ROP, GEVO And ACOR Traded By Insiders

Insider Trading Alert - ROP, GEVO And ACOR Traded By Insiders

Stocks with insider trader activity include ROP, GEVO and ACOR

Acorda Therapeutics To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference

Acorda Therapeutics To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Michael Rogers, Chief Financial Officer, will present at the Bank of America Merrill Lynch 2015 Health Care Conference in Las Vegas on Tuesday, May 12 at 3:40pm...

Acorda Therapeutics To Present At The Deutsche Bank 40th Annual Health Care Conference

Acorda Therapeutics To Present At The Deutsche Bank 40th Annual Health Care Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Michael Rogers, Chief Financial Officer, will present at the Deutsche Bank 40 th Annual Health Care Conference in Boston on Thursday, May 7 at 10:40 am.

Acorda Therapeutics (ACOR) Highlighted As Weak On High Volume

Acorda Therapeutics (ACOR) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a weak on high relative volume candidate

Acorda Reports First Quarter 2015 Financial Results

Acorda Reports First Quarter 2015 Financial Results

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced its financial results for the first quarter ended March 31, 2015.

TheStreet Quant Rating: D (Sell)